A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN) + BEVACIZUMAB (AVASTIN) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ESMERALDA
- 11 Oct 2016 Results of this study, presented at the 41st European Society for Medical Oncology Congress.
- 16 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 14 Jan 2015 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov.